Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; methylcellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; sodium starch glycollate type a; methylcellulose; magnesium stearate; macrogol 6000; microcrystalline cellulose; lactose monohydrate; purified talc; basic butylated methacrylate copolymer - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; hypromellose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Italy - Italian - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - amisulpride - amisulpride

France - French - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

mylan sas - amisulpride 400 mg - comprimé - 400 mg - pour un comprimé > amisulpride 400 mg - antipsychotiques - classe pharmacothérapeutique : antipsychotiques - code atc : n05al05amisulpride mylan appartient à une famille de médicaments appelés antipsychotiques.ce médicament est utilisé pour traiter les personnes souffrant de schizophrénie. la schizophrénie est une maladie mentale caractérisée par certains troubles psychiques et du comportement, comme par exemple des hallucinations ou de l’agitation.

France - French - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - amisulpride 400 mg - comprimé - 400 mg - pour un comprimé > amisulpride 400 mg - antipsychotiques - classe pharmacothérapeutique : antipsychotiques, code atc : n05al05amisulpride sandoz appartient à une famille de médicaments appelés antipsychotiques.ce médicament est utilisé pour traiter les personnes souffrant de schizophrénie. la schizophrénie est une maladie mentale caractérisée par certains troubles psychiques et du comportement, comme par exemple des hallucinations ou de l’agitation.